NCT04170998View on ClinicalTrials.gov

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

PHASE3CompletedINTERVENTIONAL

Enrollment

283

Participants

Timeline

Start Date

January 2, 2020

Primary Completion Date

June 28, 2021

Study Completion Date

December 8, 2021

Conditions

Type2 Diabetes

Interventions

DRUG

Evogliptin 5mg

Participants receive Evogliptin 5mg orally once a day

DRUG

Evogliptin Placebo

Participants receive placebo to match Evogliptin 5mg orally once a day

DRUG

Dapagliflozin 10mg

Participants receive Dapagliflozin orally once a day

DRUG

Metformin ≥ 1000mg

Metformin are administered at the same dose and formulation.

Trial Locations (1)

Unknown

Seoul St, Mary's Hospital,The Catholic University of Korea, Seoul

All Listed Sponsors

lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT04170998 - Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control | Biotech Hunter | Biotech Hunter